Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non–Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial ...

Combination immune checkpoint inhibitor therapy (ICI) with ipilimumab (anti–cytotoxic T-lymphocyte–associated protein 4) + nivolumab (anti–PD-1) in untreated, metastatic melanoma has achieved a ...

Bispecific antibodies (bsAbs) have emerged as a novel class of therapeutics, offering a dual-targeting strategy to enhance the therapeutic efficacy of monoclonal antibodies, which is often limited by ...

Therapeutic advances have resulted in a growing population of childhood cancer survivors. Unfortunately, this success comes at a price. A substantial proportion of the survivors develop ...

Survivorship Care for People Affected by Advanced or Metastatic Cancer: Building on the Recent Multinational Association of Supportive Care in Cancer-ASCO Standards and Practice Recommendations The ...

Emerging Paradigms in Genitourinary Cancers: Integrating Molecular Imaging, Hypoxia-Inducible Factor–Targeted Therapies, and Antibody-Drug Conjugates in Renal Cell and Urothelial Carcinomas Pancreatic ...

Risk Stratification for Sentinel Lymph Node Positivity in Older Women With Early-Stage Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2 Neu–Negative Invasive Breast Cancer This ...

Educational Video as an Alternative to Pretest In-Person Genetic Counseling in Candidates for Cancer Genetic Testing: A Randomized Controlled Noninferiority Trial The initial data set was compiled ...

The field of rare cancer research is rapidly transforming, marked by significant progress in clinical trials and treatment strategies. Rare cancers, as defined by the National Cancer Institute, occur ...

Educational Video as an Alternative to Pretest In-Person Genetic Counseling in Candidates for Cancer Genetic Testing: A Randomized Controlled Noninferiority Trial Hepatocellular carcinoma (HCC) is the ...

Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study) R1 compared induction ...